Winnette R, Zárate V, Machnicki G, DeMuro-Mercon C, Gawlicki M, Gnanasakthy A. Patient-reported outcomes in Latin America: implementation in research and role in emerging HTA systems. Value in Health Regional Issues. 2015 Dec;8:49-55. doi: 10.1016/j.vhri.2015.03.008
Li L, Kulldorff M, Russek-Cohen E, Kawai AT, Hua W. Quantifying the impact of time-varying baseline risk adjustment in the self-controlled risk interval design. Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1304-12. doi: 10.1002/pds.3885
Doward L. PROs, payers and the 5th hurdle. Presented at the 2015 ISPOR 18th Annual European Congress; November 7, 2015. Milan, Italy.
Mauskopf JA, Mullins D, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Williams V, McLeod L, Nelson L. Advances in the evaluation of longitudinal construct validity of clinical outcome assessments. Ther Innov Regul Sci. 2015 Nov;49(6):805-12. doi: 10.1177/2168479015609103
Earnshaw S, Brogan A, Wolowacz S. Budget impact analysis II: applications & design issues. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. Previously presented at the ISPOR 20th Annual International Meeting.
Martin S, Deal LS, Fricke FU, Knight C. Rare diseases: navigating the road to approval and access. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp M, Griffiths M, Agirrezabal I, Brennan A. Cost-utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria (CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
O'Donohoe P, Lundy JJ, Gnanasakthy A, Greene A. Considerations for requiring subjects to provide a response to electronic patient-reported outcome instruments. Ther Innov Regul Sci. 2015 Nov;49(6):792-6. doi: 10.1177/2168479015609647
Gnanasakthy A, Doward L, Bal V, Fricke FU. How to bring PRO data into payer decision making: PRO strategies in pharmaceutical development. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Copley-Merriman K. Value for money: health economics. Presented at the University of Michigan; October 29, 2015. Ann Arbor, MI.
Perez-Gutthann S. Risk minimization evaluation studies: perspective of a research center. Presented at the Drug Information Association 9th European Forum for Qualified Persons Responsible For Pharmacovigilance; October 13, 2015. London, England.
Dickinson KL, Patil SR, Pattanayak SK, Poulos C, Yang JH. Nature's call: impacts of sanitation choices in Orissa, India. Econ Dev Cult Change. 2015 Oct;64(1):1-29.
Mathes M. Leaving manual referencing behind: embracing EndNote. Presented at the 2015 AMWA Medical Writing & Communication Conference; September 30, 2015. San Antonio, TX.
Mathes M. Advanced Endnote tips and tricks. Presented at the 2015 AMWA Medical Writing & Communication Conference; September 30, 2015. San Antonio, TX.
Perez-Gutthann S. Role of the German pharmacoepidemiology research database in pharmacoepidemiology. Presented at the Leibniz Bremen Institute of Social and Preventive Medicine; September 17, 2015. Bremen, Germany.
Dallas A, Martin A. Establishing an editorial process: tools for success. Poster presented at the 75th Annual Conference of the American Medical Writers Association (AMWA); September 15, 2015. San Antonio, TX.
Lothman K, Martin A. Taming the beast: managing complex, multiauthor edits. Poster presented at the 75th Annual Conference of the American Medical Writers Association (AMWA); September 15, 2015. San Antonio, TX.
Siepert SD, Lothman KD, Martin A. Zombie rules and shibboleths: exploring a few contested rules of English grammar. Poster presented at the 75th Annual Conference of the American Medical Writers Association (AMWA); September 15, 2015. San Antonio, TX.
Perez-Gutthann S. Overview of large healthcare databases. Presented at the London School of Hygiene and Tropical Medicine; September 14, 2015. London, United Kingdom.
Hauber AB, Gilsenan A, Juhaeri J, Zhong Y, Noel B. Benefit risk assessment: understanding and using patient preference methodologies. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Kawai AT, Calderwood MS, Jin R, Soumerai SB, Vaz LE, Goldmann D, Lee GM. Impact of the Centers for Medicare and Medicaid Services hospital-acquired conditions policy on billing rates for 2 targeted healthcare-associated infections. Infect Control Hosp Epidemiol. 2015 Aug;36(8):871-7. doi: 10.1017/ice.2015.86
Marcano Belisario JS, Jamsek J, Huckvale K, O'Donoghue J, Morrison CP, Car J. Comparison of self-administered survey questionnaire responses collected using mobile apps versus other methods. Cochrane Database Syst Rev. 2015 Jul;27(7):MR000042. doi: 10.1002/14651858.MR000042.pub2
Arana A. The ENCePP methods guide. Presented at the Joint DIA/EMA Information Day on Post-Authorisation Studies (PAS); June 5, 2015. London, United Kingdom.
Smith RB, Bennett JE, Rantakokko P, Martinez D, Nieuwenhuijsen MJ, Toledano MB. The relationship between MX [3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone], routinely monitored trihalomethanes, and other characteristics in drinking water in a long-term survey. Environ Sci Technol. 2015 Jun 2;49(11):6485-93. doi: 10.1021/es5062006
Vaz LE, Kleinman KP, Kawai AT, Jin R, Kassler WJ, Grant PS, Rett MD, Goldmann DA, Calderwood MS, Soumerai SB, Lee GM. Impact of Medicare's Hospital-Acquired Condition policy on infections in safety net and non-safety net hospitals. Infect Control Hosp Epidemiol. 2015 Jun;36(6):649-55. doi: 10.1017/ice.2015.38.
Mauskopf JA, Earnshaw SR, Mullins D. Introduction to budget impact analysis: a 6-step approach. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. Previously presented at the ISPOR 19th Annual International Meeting.
Wolowacz S, Briggs A, Doward L. Measurement of health state utility values for economic models in clinical studies – findings of the good practices task force. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Odom DM, McLeod LD, Sherif BN, Nelson LM. Methods to assess the association of patient-reported outcomes and clinical endpoints. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Wang J, Odom D, Chirila C, Zheng Q. Evaluation of matching-adjusted indirect comparison implemented by a resampling method. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Hogue S, Brogan AP, DeMuro C, Barrett A, D'Alessio D, Bal V. Influence of patient-reported outcomes on market access decisions in decentralized markets (Brazil, Italy, Spain, and the United States). Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A212.
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015 May;29(4):529-33. doi: 10.1016/j.jdiacomp.2014.12.009
Earnshaw SR, Brogan AJ, Wolowacz SE. Budget impact analysis II: applications and design issues. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
White C, Taychakhoonavudh S, Parikh RC, Franzini L. Roles of prices, poverty, and health in medicare and private spending in Texas. Am J Manag Care. 2015 May 1;21(5):e303-11.
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins J, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from clinicaltrials.gov (2007-2013). Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2015 Apr 18;43:1-9. doi: 10.1016/j.cct.2015.04.004
Triguero-Mas M, Dadvand P, Cirach M, Martinez D, Medina A, Mompart A, Basagana X, Grazuleviciene R, Nieuwenhuijsen MJ. Natural outdoor environments and mental and physical health: relationships and mechanisms. Environ Int. 2015 Apr;77:35-41. doi: 10.1016/j.envint.2015.01.012
Gnanasakthy A, DeMuro-Mercon CJ. Logistical considerations for intergrating patient-reported outcomes in multiregional clinical trials. Clinical Researcher. 2015 Apr;45-8.
Smith VK, Mansfield CA. The design of benefit cost “architecture” for homeland security policy analysis. In: Mansfield C, Smith VK, editors. Benefit-cost analyses for security policies: does increased safety have to reduce efficiency? Cheltenhen: United Kingdom. Edward Elgar Publishing; 2015.
Mansfield CA, Smith VK. Introducing the issues: Meeting the challenges in evaluating homeland security policy. In: Mansfield C, Smith VK, editors. Benefit-cost analyses for security policies: does increased safety have to reduce efficiency? Cheltenhen: United Kingdom. Edward Elgar Publishing; 2015.
Mansfield CA, Smith VK. What we know and what we need to learn. In: Mansfield C, Smith VK, editors. Benefit-cost analyses for security policies: does increased safety have to reduce efficiency? Cheltenhen: United Kingdom. Edward Elgar Publishing; 2015.
Candrilli SD. Real-world data for health economics and outcomes research studies: an overview. Presented at the Duquesne University Graduate Student Pharmacoeconomics Seminar; March 16, 2015. Pittsburgh, PA.
Gilsenan AW. European guideline on Good Pharmacovigilance Practices (GVP) – Module XVI – risk minimization measures. Presented at the SCOPE Summit for Clinical Ops Executives; February 25, 2015. Orlando, FL.
Gilsenan AW. Observational data collection studies: considerations to minimize bias. Presented at the SCOPE Summit for Clinical Ops Executives; February 24, 2015. Orlando, FL.
Franzini L, Taychakhoonavudh S, Parikh R, White C. Medicare and private spending trends from 2008 to 2012 diverse in Texas. Med Care Res Rev. 2015 Feb;72(1):96-112.
Freeman E, Gilsenan AW. Assess the European guideline on good pharmacovigilance practices (GVP) – module XVI – risk minimization measures. Presented at the 7th Risk Evaluation and Mitigation Strategies Summit (REMS Summit); January 22, 2015. Arlington, VA.
Petrillo J, Cano S, McLeod LD, Coon C. Using classical test theory, item response theory, and rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. Value Health. 2015 Jan;18(1):25-34. doi: 10.1016/j.jval.2014.10.005
Rothman KJ. Epidemiology at 25 years. Epidemiology. 2015 Jan;26(1):1-3. doi: 10.1097/EDE.0000000000000214
Mansfield CA, Smith VK. Benefit–cost analyses for security policies. Cheltenham: United Kingdom. Edward Elgar Publishing; 2015.
Rothman M, Gnanasakthy A, Wicks P, Papadopoulos EJ. Can we use social media to support content validity of patient-reported outcome instruments in medical product development? Value Health. 2015 Jan;18(1):1-4. doi: 10.1016/j.jval.2014.10.001